Leach assumed the role of CEO officially on Jan. 1. He has been serving as CEO in an interim capacity since his predecessor, Kevin Sayer, took a leave of absence in September. In July, the company announced that he was set to take the role permanently at the start of 2026 as part of Dexcom’s planned succession process.
“I’ve had the honor of playing a role in shaping Dexcom’s industry-defining innovation since joining the company more than 20 years ago. From building the technology as an engineer in my early days, to advancing global scale to meet our long-term growth demand as COO, it’s an honor to step into the role of CEO during such a pivotal moment for the business—and a growing global metabolic health crisis,” said Leach. “I look forward to further advancing Dexcom’s long legacy of empowering people to take control of health.”
Read more about Dexcom and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Visit here to purchase our Medtech Market Special Report on CGMs.
Future developments include a redesigned app experience for the company’s Stelo over-the-counter (OTC) continuous glucose monitor (CGM). The company said it invested significantly in AI-enabled features to personalize insights and the user experience.
Following the initial launch of the company’s G7 15 Day CGM, Dexcom also expects to increase availability of that product. It egan shipping to pharmacies at the start of this month.
Dexcom also added glucose biosensing coverage for millions of people with diabetes and it said it remains committed to achieving even more coverage, increasing access to glucose biosensors for anyone with diabetes.
